Environmental microbiology

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Bacteriology, Biology, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biofilm, Antimicrobial

The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Bacteriology, Biology, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biofilm, Antimicrobial

KEELE, England, Aug. 4, 2021 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the Musculoskeletal Infection Society's 31st Annual Open Scientific Meeting, which is being held in Fort Lauderdale 6-7 August 2021. The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Avalife Is Supporting the Brain Through the Stomach

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Anatomy, Digestive system, Environmental microbiology, Firmicutes, Microbiomes, Organs anatomy), Brain, Gut–brain axis, Mental health

In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.

Key Points: 
  • In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.
  • A growing body of research has revealed how closely the brain and the gut work together a phenomenon known as the "gut-brain axis."
  • About Avalife: Avalife's parent company, Avacare Global, was founded by Dr. Vikram Naik in South Africa in 1997.
  • Avacare is the company's division that is focused on holistic solutions and targets natural and complementary medicine in pursuit of that end.

Ancilia Biosciences Awarded NSF Grant to Advance Platform Designed to Address Overlooked Obstacle to Success for Microbiome Therapeutics

Retrieved on: 
Tuesday, August 3, 2021
Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Bacteriophage, Biology, Gut microbiota, Organisms, Articles, Microbiome

We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.

Key Points: 
  • We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
  • There is evidence that phages are associated with disease and that they may also compromise the efficacy of LBPs.
  • We are delighted that the NSF sees potential in our technology and is supporting further development of our platform."
  • Ancilia Biosciences ( www.anciliabio.com) is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome and treat disease.

The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases

Retrieved on: 
Wednesday, July 28, 2021
Microbiology, Microbiomes, Bacteriology, Branches of biology, Dutch inventions, Bacteria, Environmental microbiology, Microbiota, Microbiome, Human microbiome

The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.

Key Points: 
  • The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.
  • Biocodex currently holds 20 subsidiaries (including Biocodex Canada Inc. based in Montral Quebec) and multiple long-term partnerships spanning more than 124 countries.
  • The Biocodex Microbiota Foundation is a non-profit, general interest organization that supports research into microbiota and their interaction with various pathologies.
  • Projects investigating the implication of microbiota in human health are selected annually by committees of independent international scientists.

CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University

Retrieved on: 
Tuesday, July 27, 2021
Software, Biotechnology, Pharmaceutical, Health, Technology, University, Genetics, Education, Microbiology, Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Medical specialties, Microbiome, Human microbiome, Gut microbiota, Human Microbiome Project

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
  • The ability to study the human microbiome and its effects on human health is an area of great research interest and a pivotal application for OOC technology.
  • Modelling the human microbiome in the laboratory is challenging, especially since many of its several thousand strains of bacteria cannot grow or survive when exposed to oxygen.
  • Dr David Hughes, CEO, CN Bio, commented: We are rapidly coming to appreciate the important role the microbiome plays in human health and disease.

Virtual Lecture on First-of-its-Kind Research Exploring the Influence of Pet Ownership on the Gut Microbiome

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Microbiomes, Microbiology, Bacteriology, Medical specialties, Environmental microbiology, Digestive system, Gut microbiota, Microbiota, Human microbiome, Cardiovascular disease, Microbiome

WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.

Key Points: 
  • WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.
  • This lecture, titled "The association of pet ownership, the gut microbiome, and cardiovascular disease risk among older adults", features Dr. Katharine Watson, MA, BVMS, discussing her active HABRI-funded study, "The influence of pet ownership on gut microbiota composition and cardiovascular disease risk among 50 to 85-year old United States adults".
  • The human microbiota is made up of trillions of cells, with the biggest populations residing in the gut.
  • Much of the science on the physical health benefits of pets involve the association between pet ownership and physical activity.

Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Bacteriology, Biofilm, Biological matter, Environmental microbiology, Environmental soil science, Membrane biology, Biology

WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the Company or Kane Biotech), today announces that it has cancelled 8,470,555 stock options of the Company (the Cancelled Options) of various directors, officers, employees and consultants of the Company.

Key Points: 
  • WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the Company or Kane Biotech), today announces that it has cancelled 8,470,555 stock options of the Company (the Cancelled Options) of various directors, officers, employees and consultants of the Company.
  • The Company also wishes to announce the issuance of 10,739,488 restricted share units of the Company (RSUs) to various directors, officers, employees and consultants of the Company pursuant to the performance and restricted share unit plan of the Company dated April 21, 2021.
  • Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactive+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Vedanta Biosciences Completes $68 Million Series D Financing

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Microbiomes, Microbiology, Branches of biology, Bacteriology, Dutch inventions, Environmental microbiology, Microbiome, Microscopy, Human microbiome, Magnetar Capital

Vedanta Biosciences , Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update.

Key Points: 
  • Vedanta Biosciences , Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update.
  • The Series D financing was led by affiliates of Magnetar Capital.
  • We are delighted to welcome the new investors in our Series D round and are grateful to our existing shareholders and partners for their continued support, said Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences.
  • Vedanta Biosciences is developing a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome.

MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies

Retrieved on: 
Tuesday, July 20, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Microbiome, Microbiomes, Environmental microbiology, Bacteriology

Initiated during the Summer of 2020, Plan France Relance was established to make strategic investments in critical sectors of French industry, including Health.

Key Points: 
  • Initiated during the Summer of 2020, Plan France Relance was established to make strategic investments in critical sectors of French industry, including Health.
  • The France Relance program will support the development of our unique and innovative industrial processes that leverage all the functional diversity of the microbiome to deliver better outcomes in cancer treatment.
  • Ultimately, MaaT Pharmas manufacturing platform may be used to deliver a large range of microbiome ecosystem therapies in various indications.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.